Topical therapy for oropharyngeal symptoms of myasthenia gravis
- 1 February 1986
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 19 (2) , 192-194
- https://doi.org/10.1002/ana.410190214
Abstract
Inhibitors of acetylcholinesterase are commonly used in the treatment of myasthenia gravis. We studied a patient with mainly bulbar myasthenia gravis who did not tolerate oral pyridostigmine despite a clear clinical response. Treatment with nebulized pyridostigmine reduced her symptoms without systemic side effects. This route of therapy may benefit other patients.This publication has 7 references indexed in Scilit:
- Steady state kinetics of pyridostigmine in myasthenia gravisNeurology, 1984
- Therapeutic aerosols 1--physical and practical considerations.Thorax, 1983
- Myasthenia Gravis Pathogenesis and Current Concepts in ManagementDrugs, 1983
- Pharmacologic Enhancement of Neuromuscular Transmission in Myasthenia GravisClinical Neuropharmacology, 1982
- The relationship of plasma levels of pyridostigmine to clinical effect in patients with myasthenia gravisJournal of Neurology, Neurosurgery & Psychiatry, 1981
- Clinical Application of Aerosols in Pediatrics 1–3American Review of Respiratory Disease, 1980
- Malabsorption of pyridostigmine in patients with myasthenia gravisNeurology, 1977